All > Ovarian Cancer

2X-121 for Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Ovarian Cancer2X-121 - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will test the effectiveness of 2X-121, given as a pill once daily, as a treatment for ovarian cancer in patients predicted to respond well to the drug.

Eligible Conditions
  • Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Neratinib at RP2D
1
TORL-1-23
1
kisspeptin 112-121

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: evaluated after up to approximately 2 years

Year 2
Quality of Life measurement
Year 2
Clinical benefit rate (CBR)
Correlation between 2X-121 DRP® and clinical outcome
Duration of response
Objective response rate (ORR)
Overall survival
Progression free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Neratinib at RP2D
1
TORL-1-23
1
kisspeptin 112-121

Trial Design

1 Treatment Group

2X-121
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: 2X-121 · No Placebo Group · Phase 2

2X-121Experimental Group · 2 Interventions: 2X-121, 2X-121 DRP® · Intervention Types: Drug, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: evaluated after up to approximately 2 years

Who is running the clinical trial?

Allarity TherapeuticsLead Sponsor
7 Previous Clinical Trials
268 Total Patients Enrolled
1 Trials studying Ovarian Cancer
60 Patients Enrolled for Ovarian Cancer
Amarex Clinical ResearchOTHER
23 Previous Clinical Trials
1,542 Total Patients Enrolled
1 Trials studying Ovarian Cancer
60 Patients Enrolled for Ovarian Cancer
Alcedis GmbHIndustry Sponsor
6 Previous Clinical Trials
521 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be between the ages of 18 and 50 years.
A 2X-121 DRP® using Fixed in Formalin and Embedded in Paraffin (FFPE) archival or the latest tumor tissue with an outcome measured as being in the upper 50% likelihood of response.
You have a performance status of ECOG ≤ 1.
You have an absolute neutrophil count of at least 2.5 x 10/L.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top